Electrolyte emergencies
Verified clinical guidelines and emergency management protocols.
Protocol Content
Navigation
β‘ ELECTROLYTE EMERGENCIES
COMPREHENSIVE DUAL-LEVEL CARE PROTOCOL
PRIMARY CARE → SECONDARY CARE
π For Doctors Only | Not for Public Use
Covers: Hyperkalemia | Hypokalemia | Hyponatremia | Hypernatremia | Hypocalcemia | Hypercalcemia
π° SYMBOL LEGEND
| Symbol | Meaning |
|---|---|
|
β
|
Common / Characteristic / Present |
|
β
|
Absent / Not seen / Rare |
|
β οΈ
|
Variable / Sometimes present / Caution |
π₯ LEVEL OF CARE OVERVIEW
| Procedure/Action | Primary Care | Secondary/Tertiary Care |
|---|---|---|
| Clinical recognition |
β
|
β
|
| ECG interpretation |
β
|
β
|
| IV Calcium gluconate (hyperkalemia) |
β
|
β
|
| IV Dextrose-Insulin (hyperkalemia) |
β
|
β
|
| IV Potassium replacement |
β οΈ (peripheral, slow)
|
β
(central line, faster)
|
| IV Calcium replacement |
β οΈ (peripheral)
|
β
|
| Hypertonic saline (3% NaCl) |
β οΈ (if available)
|
β
|
| Hemodialysis |
β
|
β
|
| Central venous access |
β
|
β
|
| ICU monitoring |
β
|
β
|
β±οΈ CRITICAL TIME TARGETS
| Electrolyte Emergency | Critical Action | Target Time |
|---|---|---|
|
Severe Hyperkalemia (KβΊ > 6.5 + ECG changes)
|
IV Calcium gluconate |
Immediate (within 2-3 min)
|
|
Symptomatic Hyponatremia (seizures)
|
Hypertonic saline |
Immediate
|
|
Symptomatic Hypocalcemia (tetany/seizures)
|
IV Calcium gluconate |
Immediate
|
|
Severe Hypokalemia with arrhythmia
|
IV Potassium |
Immediate
|
|
Severe Hypercalcemia
|
IV fluids + Bisphosphonate |
Within 1-2 hours
|
π NORMAL ELECTROLYTE VALUES
| Electrolyte | Normal Range | Critical Low | Critical High |
|---|---|---|---|
|
Sodium (NaβΊ)
|
135-145 mEq/L
|
< 120 mEq/L
|
> 160 mEq/L
|
|
Potassium (KβΊ)
|
3.5-5.0 mEq/L
|
< 2.5 mEq/L
|
> 6.5 mEq/L
|
|
Calcium (Total)
|
8.5-10.5 mg/dL
|
< 7.0 mg/dL
|
> 14 mg/dL
|
|
Calcium (Ionized)
|
4.5-5.5 mg/dL (1.1-1.4 mmol/L)
|
< 3.2 mg/dL
|
> 6.0 mg/dL
|
|
Magnesium (Mg²βΊ)
|
1.5-2.5 mg/dL
|
< 1.0 mg/dL
|
> 4.0 mg/dL
|
|
Phosphate (POβ³β»)
|
2.5-4.5 mg/dL
|
< 1.0 mg/dL
|
> 7.0 mg/dL
|
π΄ SECTION 1: HYPERKALEMIA
β οΈ Most immediately life-threatening electrolyte emergency β can cause fatal arrhythmias within minutes
1οΈβ£ DEFINITION & CLASSIFICATION
| Severity | Potassium Level | Risk |
|---|---|---|
|
Mild
|
5.0-5.9 mEq/L
|
Low
|
|
Moderate
|
6.0-6.4 mEq/L
|
Moderate
|
|
Severe
|
≥ 6.5 mEq/L
|
High
|
|
With ECG changes
|
Any level with ECG changes
|
Critical
|
π ECG changes are more important than absolute KβΊ level
2οΈβ£ CAUSES OF HYPERKALEMIA
Common Causes (Mnemonic: "MACHINE")
| Letter | Cause | Examples |
|---|---|---|
|
M
|
Medications | ACE-I, ARBs, KβΊ-sparing diuretics, NSAIDs, TMP-SMX, Heparin, Digoxin toxicity |
|
A
|
Acidosis | Metabolic acidosis (KβΊ shifts out of cells) |
|
C
|
Cellular destruction | Rhabdomyolysis, Tumor lysis, Hemolysis, Burns, Trauma |
|
H
|
Hypoaldosteronism | Addison's disease, Type 4 RTA |
|
I
|
Intake (excessive) | IV KβΊ supplementation, Oral supplements, Salt substitutes |
|
N
|
Nephrons (kidney failure) | Acute or Chronic Kidney Disease |
|
E
|
Excretion (reduced) | Renal failure, Obstruction |
India-Specific Common Causes
| Cause | Notes |
|---|---|
|
CKD (very common)
|
High burden in India; often undiagnosed |
|
ACE-I / ARB use
|
Common in HTN/DM patients |
|
Traditional medicines
|
May contain KβΊ |
|
Rhabdomyolysis
|
Heat stroke, snake bite, infections |
|
Dietary
|
Coconut water, banana excess in renal patients |
|
Potassium supplements
|
Over-the-counter availability |
Pseudohyperkalemia (False Elevation)
| Cause | Mechanism |
|---|---|
|
Hemolyzed sample
|
Most common; repeat sample |
|
Prolonged tourniquet
|
Causes local hemolysis |
|
Fist clenching
|
Releases KβΊ from muscle |
|
Thrombocytosis / Leukocytosis
|
KβΊ released during clotting |
|
Delayed processing
|
KβΊ leaks from RBCs |
π If KβΊ is unexpectedly high without clinical/ECG correlate, repeat the sample before treating
3οΈβ£ CLINICAL FEATURES
| System | Symptoms/Signs |
|---|---|
|
Cardiovascular
|
Arrhythmias, bradycardia, hypotension, cardiac arrest |
|
Neuromuscular
|
Weakness, paresthesias, ascending paralysis (mimics GBS) |
|
GI
|
Nausea, vomiting, diarrhea |
|
Often
|
Asymptomatic until severe/cardiac events
|
β οΈ Cardiac manifestations can occur without warning
4οΈβ£ ECG CHANGES IN HYPERKALEMIA (Progressive)
| KβΊ Level (mEq/L) | ECG Changes |
|---|---|
|
5.5-6.5
|
Tall, peaked T waves ("tenting") |
|
6.5-7.0
|
Prolonged PR interval |
| Flattened or absent P waves | |
|
7.0-8.0
|
Widened QRS complex |
| "Sine wave" pattern | |
|
> 8.0
|
Ventricular fibrillation, Asystole |
ECG Progression Visual
Normal → Peaked T → ↑PR → Flat P → Wide QRS → Sine Wave → VF/Asystole
KβΊ 5.5 6.0 6.5 7.0 7.5 8.0+
π Get ECG in ALL patients with KβΊ > 5.5 β ECG changes guide urgency
5οΈβ£ HYPERKALEMIA β PRIMARY CARE MANAGEMENT
Immediate Assessment
| Action | Details |
|---|---|
|
Confirm true hyperkalemia
|
Repeat sample if unexpected; check for hemolysis |
|
ECG
|
Look for changes (peaked T, wide QRS, flat P) |
|
Vitals
|
HR, BP, rhythm |
|
Symptoms
|
Weakness, palpitations |
|
Cause
|
Medications, renal function, diet |
Treatment Algorithm by Severity
| Scenario | Immediate Action |
|---|---|
|
KβΊ > 6.5 OR any ECG changes
|
Calcium gluconate FIRST → then shift KβΊ → then remove KβΊ
|
|
KβΊ 6.0-6.4, no ECG changes
|
Shift KβΊ (Insulin-Dextrose, Salbutamol) → Remove KβΊ |
|
KβΊ 5.5-5.9, asymptomatic
|
Remove KβΊ (diuretics, dietary restriction); monitor |
Step-by-Step Treatment Protocol
| Step | Treatment | Purpose | Onset | Duration |
|---|---|---|---|---|
| 1 |
Calcium Gluconate
|
Stabilize cardiac membrane |
1-3 min
|
30-60 min
|
| 2 |
Insulin + Dextrose
|
Shift KβΊ into cells |
15-30 min
|
4-6 hrs
|
| 3 |
Salbutamol (nebulized)
|
Shift KβΊ into cells |
15-30 min
|
2-4 hrs
|
| 4 |
Sodium Bicarbonate
|
Shift KβΊ (if acidotic) |
30-60 min
|
2-4 hrs
|
| 5 |
Diuretics / Kayexalate
|
Remove KβΊ from body |
Hours
|
Hours
|
| 6 |
Dialysis
|
Remove KβΊ (definitive) |
Immediate effect
|
As long as needed
|
Detailed Drug Dosing
Step 1: Calcium Gluconate (Cardioprotection)
| Parameter | Details |
|---|---|
|
Indication
|
KβΊ ≥ 6.5 OR any ECG changes |
|
Dose
|
10 mL of 10% Calcium Gluconate (1 g = 10 mL) |
|
Route
|
IV slow push over 2-3 min |
|
Onset
|
1-3 minutes |
|
Duration
|
30-60 minutes |
|
Repeat
|
May repeat in 5-10 min if ECG changes persist |
|
Monitoring
|
ECG during administration |
β οΈ If on Digoxin: Give more slowly (over 20-30 min) in D5W β rapid calcium can precipitate digoxin toxicity
Calcium Gluconate vs Calcium Chloride
| Preparation | Elemental Calcium | Notes |
|---|---|---|
|
Calcium Gluconate 10% (preferred)
|
90 mg per 10 mL
|
Safer for peripheral IV; less tissue necrosis |
|
Calcium Chloride 10%
|
270 mg per 10 mL
|
3× more calcium; use via central line only |
Step 2: Insulin + Dextrose (Shift KβΊ into cells)
| Parameter | Details |
|---|---|
|
Dose
|
Regular Insulin 10 units IV + 25 g Dextrose (50 mL of 50% Dextrose) |
|
Route
|
IV |
|
Onset
|
15-30 minutes |
|
Duration
|
4-6 hours |
|
KβΊ reduction
|
0.5-1.0 mEq/L |
|
Monitoring
|
Check blood glucose at 30 min, 60 min, 2 hrs (risk of hypoglycemia) |
| Preparation | How to Give |
|---|---|
| Regular Insulin 10 units | IV bolus |
| 50% Dextrose 50 mL | IV bolus (can give via peripheral line slowly) |
| OR 25% Dextrose 100 mL | Safer for peripheral vein |
π Always give Dextrose WITH Insulin to prevent hypoglycemia
If Blood Glucose Already High (> 250 mg/dL)
| Scenario | Dextrose Dose |
|---|---|
| Glucose > 250 mg/dL |
Give Insulin alone (no dextrose)
|
| Glucose 200-250 mg/dL |
Give half dextrose (25 mL of 50%)
|
| Glucose < 200 mg/dL |
Full dextrose dose
|
Step 3: Nebulized Salbutamol (Shift KβΊ into cells)
| Parameter | Details |
|---|---|
|
Dose
|
10-20 mg nebulized (4-8 respules of 2.5 mg) |
|
Route
|
Nebulization |
|
Onset
|
15-30 minutes |
|
Duration
|
2-4 hours |
|
KβΊ reduction
|
0.5-1.0 mEq/L |
|
Caution
|
Tachycardia; use cautiously in cardiac patients |
π Synergistic with Insulin-Dextrose β use both for greater effect
Step 4: Sodium Bicarbonate (If Acidotic)
| Parameter | Details |
|---|---|
|
Indication
|
Metabolic acidosis (pH < 7.2, HCOβ < 15) |
|
Dose
|
50-100 mEq (50-100 mL of 8.4% NaHCOβ) |
|
Route
|
IV over 30-60 min |
|
Onset
|
30-60 minutes |
|
KβΊ reduction
|
Variable (0.5 mEq/L) |
|
Not effective
|
In non-acidotic patients |
β οΈ Sodium Bicarbonate is NOT first-line; only if acidosis present
Step 5: Remove KβΊ from Body
Diuretics (If Renal Function Adequate)
| Drug | Dose | Notes |
|---|---|---|
|
Furosemide
|
40-80 mg IV
|
Promotes KβΊ excretion; only if UOP present |
Potassium Binders (Remove KβΊ via GI Tract)
| Drug | Dose | Onset | Notes |
|---|---|---|---|
|
Sodium Polystyrene Sulfonate (Kayexalate)
|
15-30 g PO/PR
|
4-6 hrs
|
Slow; avoid in ileus |
|
Patiromer
|
8.4 g PO
|
7 hrs
|
Newer; better tolerated |
|
Sodium Zirconium Cyclosilicate
|
10 g PO
|
1-2 hrs
|
Fastest onset |
π Kayexalate is slow and should NOT be relied upon for acute management; use as adjunct
Dialysis (Definitive Treatment)
| Indication for Urgent Dialysis |
|---|
| KβΊ > 6.5 with ECG changes not responding to medical therapy |
| KβΊ > 7.0 mEq/L |
| Oliguric/Anuric renal failure |
| Refractory to medical management |
| Life-threatening arrhythmias |
Hyperkalemia β Primary Care Quick Protocol
| If KβΊ ≥ 6.5 OR ECG Changes | Action |
|---|---|
|
Step 1
|
Calcium Gluconate 10% β 10 mL IV over 2-3 min |
|
Step 2
|
Insulin 10 U IV + 50% Dextrose 50 mL IV |
|
Step 3
|
Salbutamol 10-20 mg nebulized |
|
Step 4
|
IV fluids if not contraindicated |
|
Step 5
|
TRANSFER for dialysis if KβΊ > 6.5 or not responding
|
Transfer Indications
| Indication |
|---|
| KβΊ > 6.5 mEq/L |
| ECG changes not resolving |
| Oliguric/Anuric renal failure |
| Refractory to initial treatment |
| Need for dialysis |
| Concurrent acidosis not correcting |
6οΈβ£ HYPERKALEMIA β SECONDARY CARE MANAGEMENT
Continued Management
| Treatment | Details |
|---|---|
| Continue Insulin-Dextrose | Monitor glucose q1h |
| Repeat Salbutamol | If still elevated |
| Dialysis | Definitive treatment; removes 25-50 mEq/hr |
| Treat underlying cause | CKD, medications, acidosis |
Monitoring
| Parameter | Frequency |
|---|---|
| KβΊ |
Every 1-2 hrs until stable
|
| ECG |
Continuous until KβΊ < 6
|
| Blood glucose |
Every 30-60 min (post insulin)
|
| Renal function |
Daily
|
Dialysis Modalities
| Modality | KβΊ Removal Rate | Notes |
|---|---|---|
|
Hemodialysis
|
25-50 mEq/hr
|
Most rapid; preferred |
|
CRRT
|
Slower
|
For hemodynamically unstable patients |
|
Peritoneal Dialysis
|
Slowest
|
If HD unavailable |
π‘ SECTION 2: HYPOKALEMIA
7οΈβ£ DEFINITION & CLASSIFICATION
| Severity | Potassium Level | Risk |
|---|---|---|
|
Mild
|
3.0-3.4 mEq/L
|
Low
|
|
Moderate
|
2.5-2.9 mEq/L
|
Moderate
|
|
Severe
|
< 2.5 mEq/L
|
High
|
8οΈβ£ CAUSES OF HYPOKALEMIA
Common Causes
| Category | Examples |
|---|---|
|
GI Losses
|
Vomiting, diarrhea, NG suction, laxative abuse |
|
Renal Losses
|
Diuretics (thiazides, loop), hyperaldosteronism, RTA |
|
Transcellular Shift
|
Insulin, β2-agonists, alkalosis, refeeding |
|
Decreased Intake
|
Malnutrition, alcoholism, anorexia |
|
Medications
|
Diuretics, amphotericin B, aminoglycosides |
India-Specific Common Causes
| Cause | Notes |
|---|---|
|
Diarrheal illness
|
Very common; GI losses |
|
Chronic diuretic use
|
Common in HTN/HF patients |
|
Malnutrition
|
Especially in vulnerable populations |
|
Hypokalemic Periodic Paralysis
|
Seen in thyrotoxicosis (Graves') |
|
RTA
|
Distal RTA |
|
Primary Aldosteronism
|
Underdiagnosed |
9οΈβ£ CLINICAL FEATURES
| System | Features |
|---|---|
|
Neuromuscular
|
Weakness (proximal > distal), fatigue, cramps, paralysis, rhabdomyolysis |
|
Cardiovascular
|
Arrhythmias (PACs, PVCs, AF, VT, VF), hypotension |
|
GI
|
Constipation, ileus |
|
Renal
|
Polyuria, metabolic alkalosis |
|
Respiratory
|
Respiratory muscle weakness |
π ECG CHANGES IN HYPOKALEMIA
| KβΊ Level | ECG Changes |
|---|---|
|
3.0-3.5
|
Flattened T waves |
|
2.5-3.0
|
ST depression, T wave inversion |
|
U waves (most characteristic)
|
|
|
< 2.5
|
Prolonged QT interval |
| Increased risk of Torsades de Pointes | |
| AF, VT, VF |
U Wave
Prominent U wave (> T wave amplitude) is characteristic of hypokalemia
1οΈβ£1οΈβ£ HYPOKALEMIA β PRIMARY CARE MANAGEMENT
Severity-Based Approach
| Severity | Route | Treatment |
|---|---|---|
|
Mild (3.0-3.4)
|
Oral
|
Oral KβΊ supplementation + dietary |
|
Moderate (2.5-2.9)
|
Oral or IV
|
Oral preferred; IV if symptomatic |
|
Severe (< 2.5) or symptomatic
|
IV
|
IV KCl infusion + monitoring |
|
Life-threatening (arrhythmias)
|
IV
|
Urgent IV KCl + cardiac monitoring |
Oral Potassium Replacement
| Preparation | Dose | Notes |
|---|---|---|
|
Potassium Chloride (KCl) liquid
|
20-40 mEq PO TID
|
Take with food (GI irritation) |
|
KCl slow-release tablets
|
8-20 mEq PO BD-TID
|
|
|
Potassium citrate
|
20-40 mEq PO TID
|
Use if concurrent metabolic acidosis |
Dietary Sources of Potassium
| Food | KβΊ Content (approximate) |
|---|---|
| Banana (1 medium) |
10 mEq
|
| Orange juice (1 cup) |
10 mEq
|
| Coconut water (1 cup) |
15 mEq
|
| Potato (1 medium) |
15 mEq
|
| Spinach (½ cup cooked) |
10 mEq
|
| Tomato (1 medium) |
8 mEq
|
IV Potassium Replacement
General Principles
| Principle | Details |
|---|---|
|
Concentration
|
Max 40 mEq/L via peripheral IV |
| Max 60 mEq/L via central line | |
|
Rate
|
Max 10-20 mEq/hr via peripheral IV |
| Max 40 mEq/hr via central line (with monitoring) | |
|
Monitoring
|
Continuous ECG if giving > 10 mEq/hr |
|
Recheck KβΊ
|
Every 2-4 hrs during replacement |
IV KCl Preparation
| Preparation | How to Use |
|---|---|
| KCl 20 mEq in 1 L NS | Run at 100-200 mL/hr (20-40 mEq over 10-20 hrs) |
| KCl 40 mEq in 1 L NS | Max for peripheral; run at 100 mL/hr |
| KCl 10 mEq in 100 mL NS | For faster replacement; run over 1 hr (via central preferred) |
Replacement Guide (Estimated)
| KβΊ Level | Approximate Deficit | Replacement Needed |
|---|---|---|
|
3.0-3.5
|
100-200 mEq
|
40-80 mEq
|
|
2.5-3.0
|
200-400 mEq
|
80-120 mEq
|
|
2.0-2.5
|
400-600 mEq
|
120-200 mEq
|
|
< 2.0
|
> 600 mEq
|
> 200 mEq
|
π For every 0.3 mEq/L drop in serum KβΊ below 3.5, total body KβΊ deficit is ~100 mEq
Correct Concurrent Magnesium Deficiency
| Key Point |
|---|
|
Hypomagnesemia causes refractory hypokalemia
|
| Check Mg²βΊ in all hypokalemic patients |
| Correct Mg²βΊ before/with KβΊ replacement |
| Drug | Dose | Route |
|---|---|---|
|
Magnesium Sulfate
|
2-4 g
|
IV over 1-2 hrs
|
|
Magnesium Oxide
|
400-800 mg
|
PO daily
|
Hypokalemia β Primary Care Quick Protocol
| Scenario | Action |
|---|---|
|
Mild (KβΊ 3.0-3.4)
|
Oral KCl 40-60 mEq/day + dietary; recheck in 2-3 days |
|
Moderate (KβΊ 2.5-2.9)
|
Oral KCl 60-80 mEq/day; consider IV if symptomatic |
|
Severe (KβΊ < 2.5)
|
IV KCl 20-40 mEq in 1L NS over 2-4 hrs; TRANSFER
|
|
With arrhythmias
|
IV KCl urgently + TRANSFER immediately
|
Transfer Indications
| Indication |
|---|
| KβΊ < 2.5 mEq/L |
| Symptomatic (weakness, paralysis, arrhythmias) |
| ECG changes |
| Need for rapid IV replacement (> 10 mEq/hr) |
| Concurrent hypomagnesemia not correcting |
| Refractory to oral replacement |
1οΈβ£2οΈβ£ HYPOKALEMIA β SECONDARY CARE MANAGEMENT
Severe Hypokalemia Protocol
| Step | Action |
|---|---|
| 1 | Central line access (if rapid replacement needed) |
| 2 | KCl 20-40 mEq IV over 1-2 hrs (with cardiac monitoring) |
| 3 | Recheck KβΊ after every 40-60 mEq given |
| 4 | Correct hypomagnesemia concurrently |
| 5 | Identify and treat underlying cause |
Monitoring
| Parameter | Frequency |
|---|---|
| KβΊ |
Every 2-4 hrs during active replacement
|
| Mg²βΊ |
Every 6-12 hrs
|
| ECG |
Continuous if severe or arrhythmias
|
| Urine output |
Hourly
|
π΅ SECTION 3: HYPONATREMIA
1οΈβ£3οΈβ£ DEFINITION & CLASSIFICATION
By Severity
| Severity | Sodium Level |
|---|---|
|
Mild
|
130-134 mEq/L
|
|
Moderate
|
125-129 mEq/L
|
|
Severe
|
< 125 mEq/L
|
|
Critical
|
< 120 mEq/L
|
By Onset
| Type | Onset | Risk |
|---|---|---|
|
Acute
|
< 48 hrs
|
High risk of cerebral edema; can correct faster
|
|
Chronic
|
> 48 hrs
|
Risk of osmotic demyelination if corrected too fast
|
|
Unknown
|
Unknown
|
Assume chronic; correct slowly
|
By Volume Status
| Type | Volume Status | Causes |
|---|---|---|
|
Hypovolemic
|
↓ TBW, ↓↓ NaβΊ
|
Diarrhea, vomiting, diuretics, burns |
|
Euvolemic
|
Normal TBW
|
SIADH, hypothyroid, adrenal insufficiency |
|
Hypervolemic
|
↑↑ TBW, ↑ NaβΊ
|
Heart failure, cirrhosis, nephrotic syndrome |
1οΈβ£4οΈβ£ CAUSES OF HYPONATREMIA
By Volume Status
| Hypovolemic | Euvolemic | Hypervolemic |
|---|---|---|
| Vomiting |
SIADH
|
Heart failure |
| Diarrhea | Hypothyroidism | Cirrhosis |
| Diuretics | Adrenal insufficiency | Nephrotic syndrome |
| Burns | Polydipsia | Renal failure |
| Third-spacing | Medications |
SIADH Causes (Common)
| Category | Examples |
|---|---|
|
CNS
|
Stroke, trauma, meningitis, SAH |
|
Pulmonary
|
Pneumonia, TB, lung cancer |
|
Malignancy
|
Small cell lung cancer, pancreatic cancer |
|
Drugs
|
SSRIs, Carbamazepine, Oxcarbazepine, Vincristine, Cyclophosphamide, NSAIDs |
|
Post-operative
|
Pain, nausea, hypovolemia |
India-Specific Common Causes
| Cause | Notes |
|---|---|
|
Diarrheal illness
|
Common; hypovolemic hyponatremia |
|
TB meningitis
|
SIADH |
|
Pulmonary TB
|
SIADH |
|
Medications
|
SSRIs, Carbamazepine |
|
Excessive water intake with exercise
|
Exercise-associated hyponatremia |
|
Cerebral malaria / Encephalitis
|
SIADH |
1οΈβ£5οΈβ£ CLINICAL FEATURES
| NaβΊ Level (mEq/L) | Symptoms |
|---|---|
|
130-135
|
Usually asymptomatic |
|
125-130
|
Nausea, malaise, headache |
|
120-125
|
Vomiting, confusion, drowsiness |
|
115-120
|
Seizures, obtundation |
|
< 115
|
Coma, respiratory arrest, death |
Severity of Symptoms
| Category | Features |
|---|---|
|
Mild
|
Nausea, headache, fatigue |
|
Moderate
|
Confusion, vomiting, drowsiness |
|
Severe
|
Seizures, coma, respiratory arrest |
π Rate of fall is more important than absolute level β acute drops cause more symptoms
1οΈβ£6οΈβ£ HYPONATREMIA β PRIMARY CARE MANAGEMENT
Assessment
| Step | Action |
|---|---|
| 1 | Confirm true hyponatremia (rule out pseudohyponatremia) |
| 2 | Assess volume status (hypo, eu, hypervolemic) |
| 3 | Assess symptom severity |
| 4 | Estimate acuity (acute vs chronic) |
Pseudohyponatremia
| Cause | Mechanism | Action |
|---|---|---|
| Hyperglycemia | Dilutional | Correct for glucose |
| Hyperlipidemia | Lab artifact | Use direct ion-selective electrode |
| Hyperproteinemia | Lab artifact | Use direct ion-selective electrode |
Corrected Sodium (for Hyperglycemia)
Corrected NaβΊ = Measured NaβΊ + [1.6 × (Glucose - 100) / 100]
| Measured NaβΊ | Glucose | Corrected NaβΊ |
|---|---|---|
| 130 | 500 |
130 + (1.6 × 4) = 136.4
|
| 125 | 800 |
125 + (1.6 × 7) = 136.2
|
Treatment Based on Symptoms & Acuity
| Scenario | Treatment | Rate of Correction |
|---|---|---|
|
Severe symptoms (seizures, coma)
|
Hypertonic saline (3% NaCl)
|
1-2 mEq/L/hr for 2-3 hrs
|
|
Moderate symptoms
|
3% NaCl or NS (based on volume) |
Max 10-12 mEq/L in 24 hrs
|
|
Mild/Asymptomatic
|
Treat underlying cause |
Max 8 mEq/L in 24 hrs
|
|
Chronic (> 48 hrs)
|
Slow correction |
Max 8 mEq/L in 24 hrs
|
Hypertonic Saline (3% NaCl) Protocol
When to Use
| Indication |
|---|
| Severe symptomatic hyponatremia (seizures, coma, severe confusion) |
| NaβΊ < 120 mEq/L with neurological symptoms |
Preparation
| Preparation | How to Make |
|---|---|
|
3% NaCl (if available)
|
Use directly |
|
If not available:
|
Add 60 mL of 23.4% NaCl to 440 mL NS = 3% NaCl |
|
Or:
|
Add 30 mL of 23.4% NaCl to 500 mL NS ≈ 2.4% NaCl |
Dosing
| Parameter | Details |
|---|---|
|
Bolus for seizures
|
100 mL of 3% NaCl IV over 10 min |
| May repeat ×2 if symptoms persist | |
|
Infusion
|
0.5-2 mL/kg/hr |
|
Target rise
|
1-2 mEq/L/hr for first 2-3 hrs |
|
Max correction
|
10-12 mEq/L in first 24 hrs |
| 8 mEq/L in 24 hrs if chronic |
Example Calculation
| Weight | 3% NaCl at 1 mL/kg/hr | Expected NaβΊ rise |
|---|---|---|
|
70 kg
|
70 mL/hr
|
~1 mEq/L per hour
|
π Recheck NaβΊ every 2-4 hrs during correction
Treatment Based on Volume Status
| Volume Status | Assessment | Treatment |
|---|---|---|
|
Hypovolemic
|
Dry mucosa, ↓ skin turgor, ↓ JVP, tachycardia |
Normal Saline (0.9% NaCl)
|
|
Euvolemic
|
No signs of volume excess or deficit |
Fluid restriction (1-1.5 L/day); treat cause
|
|
Hypervolemic
|
Edema, ↑ JVP, ascites |
Fluid restriction + Diuretics; treat underlying
|
Hypovolemic Hyponatremia β NS Treatment
| Calculation | Details |
|---|---|
| Start with | NS at 100-150 mL/hr |
| Monitor | NaβΊ every 4-6 hrs |
| Expect | NaβΊ will rise as volume is repleted |
Primary Care Summary β Hyponatremia
| Scenario | Action |
|---|---|
|
Severe symptoms (seizures/coma)
|
3% NaCl 100 mL bolus × 2-3; TRANSFER immediately
|
|
Moderate symptoms
|
If hypovolemic: NS; If euvolemic: fluid restrict; TRANSFER
|
|
Mild/Asymptomatic
|
Treat underlying cause; monitor; transfer if worsening |
Transfer Indications
| Indication |
|---|
| NaβΊ < 125 mEq/L |
| Any neurological symptoms |
| Need for 3% NaCl |
| Unknown etiology |
| Not responding to initial treatment |
| Need for close monitoring |
1οΈβ£7οΈβ£ HYPONATREMIA β SECONDARY CARE MANAGEMENT
Monitoring Protocol
| Parameter | Frequency |
|---|---|
| NaβΊ |
Every 2-4 hrs during active correction
|
| Urine NaβΊ, Urine Osmolality |
At presentation; guide diagnosis
|
| Volume status |
Continuous
|
| Neurological status |
Continuous
|
Osmotic Demyelination Syndrome (ODS) Prevention
| Risk Factor for ODS |
|---|
| Chronic hyponatremia (> 48 hrs) |
| NaβΊ < 105 mEq/L |
| Hypokalemia |
| Malnutrition |
| Alcoholism |
| Liver disease |
| Prevention Strategy |
|---|
|
Correct NaβΊ by max 8 mEq/L in 24 hrs in chronic hyponatremia
|
| Max 10-12 mEq/L in 24 hrs in acute |
| If overcorrected: Give D5W or Desmopressin to lower NaβΊ back |
If Overcorrection Occurs
| Action |
|---|
| Stop hypertonic saline |
| Give D5W to lower NaβΊ back |
| Desmopressin (DDAVP) 2-4 mcg IV to prevent further rise |
| Target: Lower NaβΊ back to safe correction limit |
Specific Treatment by Cause
| Cause | Treatment |
|---|---|
|
SIADH
|
Fluid restriction; Tolvaptan (15-30 mg PO if available); Salt tablets |
|
Adrenal insufficiency
|
Hydrocortisone 100 mg IV q8h |
|
Hypothyroidism
|
Levothyroxine |
|
Heart failure
|
Fluid restriction; Diuretics; GDMT |
|
Cirrhosis
|
Fluid restriction; Avoid NSAIDs |
|
Diuretic-induced
|
Stop diuretic; Volume replacement |
π£ SECTION 4: HYPERNATREMIA
1οΈβ£8οΈβ£ DEFINITION & CLASSIFICATION
| Severity | Sodium Level |
|---|---|
|
Mild
|
146-150 mEq/L
|
|
Moderate
|
151-159 mEq/L
|
|
Severe
|
≥ 160 mEq/L
|
π Hypernatremia almost always indicates water deficit (not salt excess)
1οΈβ£9οΈβ£ CAUSES OF HYPERNATREMIA
| Category | Causes |
|---|---|
|
Decreased water intake
|
Altered mental status, no access to water, elderly, infants |
|
Increased water loss
|
Diabetes insipidus, osmotic diuresis (DKA, HHS), diarrhea, sweating, burns |
|
Increased NaβΊ intake
|
Hypertonic saline, NaHCOβ, Salt poisoning (rare) |
India-Specific Common Causes
| Cause | Notes |
|---|---|
|
Elderly with limited access to water
|
Common |
|
Heat stroke
|
Summer months |
|
Diarrheal illness
|
Especially in children |
|
DKA/HHS
|
Osmotic diuresis |
|
Altered mental status
|
Unable to drink |
2οΈβ£0οΈβ£ CLINICAL FEATURES
| System | Features |
|---|---|
|
Neurological
|
Lethargy, irritability, confusion, seizures, coma |
|
Other
|
Thirst (if conscious), dry mucous membranes, oliguria |
Severity of Symptoms
| NaβΊ Level | Features |
|---|---|
|
146-155
|
Thirst, lethargy |
|
156-165
|
Confusion, muscle twitching |
|
> 165
|
Seizures, coma, intracranial hemorrhage |
2οΈβ£1οΈβ£ HYPERNATREMIA β MANAGEMENT
Water Deficit Calculation
Water Deficit (L) = TBW × [(Measured NaβΊ / 140) - 1]
TBW = Weight (kg) × 0.6 (men) or × 0.5 (women/elderly)
| Example (70 kg male, NaβΊ = 160) |
|---|
| TBW = 70 × 0.6 = 42 L |
|
Deficit = 42 × [(160/140) - 1] = 42 × 0.14 = 6 L
|
Rate of Correction
| Type | Correction Rate | Max in 24 hrs |
|---|---|---|
|
Acute (< 24 hrs)
|
1 mEq/L/hr
|
Can be faster
|
|
Chronic (> 48 hrs)
|
0.5 mEq/L/hr
|
Max 10-12 mEq/L
|
|
Unknown
|
Assume chronic
|
Max 10 mEq/L
|
β οΈ Rapid correction of chronic hypernatremia can cause cerebral edema
Fluid Selection
| Fluid | When to Use |
|---|---|
|
D5W
|
Pure water deficit (DI, inadequate intake) |
|
0.45% NaCl
|
Volume depletion + water deficit |
|
0.9% NaCl
|
Severe hypovolemia/shock (initially); then switch |
Treatment Protocol
| Step | Action |
|---|---|
| 1 | If hypovolemic/shock: NS bolus first to restore circulation |
| 2 | Calculate water deficit |
| 3 | Replace deficit over 48-72 hrs |
| 4 | Give 50% of deficit in first 24 hrs |
| 5 | Use D5W or 0.45% NaCl |
| 6 | Add ongoing losses (urine, insensible) |
| 7 | Monitor NaβΊ every 4-6 hrs |
Infusion Rate Calculation
To lower NaβΊ by 1 mEq/L, need ~3-4 mL/kg of free water
| Example (70 kg, NaβΊ 160 → target 150 in 24 hrs) |
|---|
| Need to lower by 10 mEq/L |
| Free water needed ≈ 70 × 3.5 × 10 = 2450 mL (approximately) |
| Plus ongoing losses |
| Give as D5W or 0.45% NaCl over 24 hrs |
Monitoring
| Parameter | Frequency |
|---|---|
| NaβΊ |
Every 4-6 hrs during correction
|
| Volume status |
Continuous
|
| Urine output |
Hourly
|
| Neurological status |
Continuous
|
Primary Care Summary β Hypernatremia
| Scenario | Action |
|---|---|
|
Hypovolemic + Hypernatremia
|
NS initially until hemodynamically stable → then D5W or 0.45% NaCl |
|
Euvolemic (DI, inadequate intake)
|
D5W or 0.45% NaCl; correct slowly |
|
Severe (NaβΊ ≥ 160)
|
TRANSFER for close monitoring
|
π€ SECTION 5: HYPOCALCEMIA
2οΈβ£2οΈβ£ DEFINITION & CLASSIFICATION
| Parameter | Normal | Low |
|---|---|---|
|
Total Calcium
|
8.5-10.5 mg/dL
|
< 8.5 mg/dL
|
|
Ionized Calcium
|
4.5-5.5 mg/dL (1.1-1.4 mmol/L)
|
< 4.5 mg/dL
|
|
Severe (Symptomatic)
|
Ionized Ca < 3.2 mg/dL
|
Corrected Calcium (for Albumin)
Corrected Ca = Measured Ca + 0.8 × (4 - Albumin)
| Example | Measured Ca 7.5, Albumin 2.5 |
|---|---|
| Corrected |
7.5 + 0.8 × (4 - 2.5) = 7.5 + 1.2 = 8.7 mg/dL (normal)
|
π Always correct for albumin; or use ionized calcium
2οΈβ£3οΈβ£ CAUSES OF HYPOCALCEMIA
| Category | Causes |
|---|---|
|
PTH Deficiency
|
Post-thyroidectomy/parathyroidectomy, Autoimmune |
|
PTH Resistance
|
Pseudohypoparathyroidism |
|
Vitamin D Deficiency
|
Dietary, Malabsorption, Liver/Kidney disease |
|
Hyperphosphatemia
|
CKD, Rhabdomyolysis, Tumor lysis |
|
Chelation
|
Citrate (blood transfusion), EDTA |
|
Drugs
|
Bisphosphonates, Denosumab, Foscarnet, Cinacalcet |
|
Other
|
Acute pancreatitis, Sepsis, Hungry bone syndrome |
India-Specific Common Causes
| Cause | Notes |
|---|---|
|
Post-thyroidectomy
|
Common surgical complication |
|
Vitamin D deficiency
|
Very prevalent in India |
|
CKD
|
Secondary hyperparathyroidism with hypocalcemia |
|
Malnutrition
|
Low calcium intake |
|
Malabsorption
|
Celiac disease, tropical sprue |
2οΈβ£4οΈβ£ CLINICAL FEATURES
Symptoms & Signs
| System | Features |
|---|---|
|
Neuromuscular
|
Paresthesias (perioral, fingers, toes), muscle cramps, tetany, seizures |
|
Cardiac
|
Prolonged QT, arrhythmias, heart failure |
|
Respiratory
|
Laryngospasm, bronchospasm |
|
Psychiatric
|
Anxiety, irritability, psychosis |
|
Chronic
|
Cataracts, dental abnormalities, basal ganglia calcification |
Classic Signs
| Sign | Description | How to Elicit |
|---|---|---|
|
Chvostek's sign
|
Facial muscle twitch | Tap facial nerve anterior to ear |
|
Trousseau's sign
|
Carpal spasm | Inflate BP cuff above systolic × 3 min |
ECG Changes
| Finding |
|---|
|
Prolonged QT interval
|
| ST segment changes |
| T wave changes |
| Risk of Torsades de Pointes |
2οΈβ£5οΈβ£ HYPOCALCEMIA β MANAGEMENT
Severity Assessment
| Severity | Features | Treatment |
|---|---|---|
|
Mild (Ca 7.5-8.5, asymptomatic)
|
No symptoms | Oral calcium + Vitamin D |
|
Moderate (Ca 7-7.5 or mild symptoms)
|
Paresthesias, mild cramps | Oral or IV calcium |
|
Severe (Ca < 7 or symptomatic)
|
Tetany, seizures, laryngospasm, prolonged QT |
IV Calcium Gluconate
|
IV Calcium Replacement (Severe/Symptomatic)
Acute Treatment
| Drug | Dose | Route | Rate |
|---|---|---|---|
|
Calcium Gluconate 10%
|
1-2 g (10-20 mL)
|
IV
|
Over 10-20 min
|
|
= 90-180 mg elemental calcium
|
π Calcium Gluconate is preferred over Calcium Chloride for peripheral IV (less tissue necrosis)
Maintenance Infusion (If Ongoing Need)
| Preparation | Details |
|---|---|
| Add 6-8 ampoules (60-80 mL) of 10% Calcium Gluconate to 1 L D5W | = 0.5-0.8 mg/mL elemental calcium |
| Infuse at | 50-100 mL/hr |
| Target | Ionized Ca > 4.0 mg/dL |
Calcium Gluconate Preparation
| 10% Calcium Gluconate | Contains |
|---|---|
| 10 mL ampoule | 1 g = 90 mg elemental calcium |
| 20 mL ampoule | 2 g = 180 mg elemental calcium |
Concurrent Magnesium Replacement
| Key Point |
|---|
|
Hypomagnesemia causes refractory hypocalcemia
|
| Check Mg²βΊ in all hypocalcemic patients |
| Correct Mg²βΊ before/with Ca²βΊ replacement |
| Drug | Dose |
|---|---|
|
Magnesium Sulfate 50%
|
2-4 g IV over 30-60 min
|
Oral Calcium Replacement (Mild/Maintenance)
| Preparation | Elemental Ca | Dose |
|---|---|---|
|
Calcium Carbonate
|
40% |
500-1500 mg elemental Ca/day (in divided doses)
|
|
Calcium Citrate
|
21% |
Better absorbed; use if achlorhydria
|
Vitamin D Replacement
| Preparation | Dose | Notes |
|---|---|---|
|
Cholecalciferol (D3)
|
1000-4000 IU/day
|
For chronic deficiency |
|
Calcitriol
|
0.25-1 mcg/day
|
For CKD or hypoparathyroidism |
|
Alfacalcidol
|
0.25-1 mcg/day
|
Alternative to Calcitriol |
Monitoring
| Parameter | Frequency |
|---|---|
| Ionized Ca or total Ca |
Every 4-6 hrs during IV replacement
|
| Mg²βΊ |
Every 6-12 hrs
|
| ECG |
Continuous if severe or QT prolonged
|
| Phosphate |
Daily
|
Caution in Hyperphosphatemia
| If Phosphate > 6 mg/dL |
|---|
| Correct phosphate first (dietary restriction, phosphate binders) |
| IV calcium can precipitate with phosphate → soft tissue/vascular calcification |
| Use lower calcium doses; correct phosphate urgently |
Primary Care Summary β Hypocalcemia
| Scenario | Action |
|---|---|
|
Severe symptoms (tetany, seizures, laryngospasm)
|
Calcium Gluconate 10% 10-20 mL IV over 10-20 min; TRANSFER
|
|
Mild symptoms
|
Oral calcium 1-2 g/day + Vitamin D; monitor |
|
Post-thyroidectomy
|
Check Ca q6-12h; IV calcium if symptomatic; TRANSFER if severe
|
π SECTION 6: HYPERCALCEMIA
2οΈβ£6οΈβ£ DEFINITION & CLASSIFICATION
| Severity | Calcium Level | Risk |
|---|---|---|
|
Mild
|
10.5-12 mg/dL
|
Low
|
|
Moderate
|
12-14 mg/dL
|
Moderate
|
|
Severe (Hypercalcemic Crisis)
|
> 14 mg/dL
|
High
|
2οΈβ£7οΈβ£ CAUSES OF HYPERCALCEMIA
Common Causes (90%)
| Cause | Mechanism |
|---|---|
|
Primary Hyperparathyroidism
|
Excessive PTH |
|
Malignancy
|
PTHrP, osteolytic metastases, calcitriol production |
Other Causes
| Category | Causes |
|---|---|
|
Vitamin D
|
Excess supplementation, Granulomatous diseases (Sarcoidosis, TB) |
|
Drugs
|
Thiazides, Lithium, Vitamin A toxicity |
|
Endocrine
|
Thyrotoxicosis, Adrenal insufficiency |
|
Immobilization
|
Prolonged bed rest |
|
Other
|
Milk-alkali syndrome, Familial hypocalciuric hypercalcemia |
India-Specific Considerations
| Cause | Notes |
|---|---|
|
Malignancy
|
Common; especially lung, breast, myeloma |
|
Primary hyperparathyroidism
|
Underdiagnosed |
|
Granulomatous disease
|
TB (common in India), Sarcoidosis |
|
Vitamin D toxicity
|
Over-supplementation (increasingly common) |
2οΈβ£8οΈβ£ CLINICAL FEATURES
Mnemonic: "Bones, Stones, Groans, and Psychiatric Moans"
| Category | Features |
|---|---|
|
Bones
|
Bone pain, fractures, osteoporosis |
|
Stones
|
Kidney stones, nephrocalcinosis |
|
Groans (GI)
|
Constipation, nausea, vomiting, pancreatitis |
|
Psychiatric Moans
|
Confusion, depression, psychosis, coma |
|
Other
|
Polyuria, polydipsia, weakness, shortened QT, arrhythmias |
Severity of Symptoms
| Ca Level | Symptoms |
|---|---|
|
10.5-12
|
Usually asymptomatic |
|
12-14
|
Polyuria, constipation, fatigue |
|
> 14
|
Confusion, lethargy, arrhythmias |
|
> 16
|
Coma, cardiac arrest |
ECG Changes
| Finding |
|---|
|
Shortened QT interval
|
| Wide T wave |
| Bradycardia, heart block |
| Osborn (J) waves (severe) |
2οΈβ£9οΈβ£ HYPERCALCEMIA β MANAGEMENT
Severity-Based Approach
| Severity | Treatment |
|---|---|
|
Mild (10.5-12, asymptomatic)
|
Treat underlying cause; encourage hydration |
|
Moderate (12-14)
|
IV fluids; consider bisphosphonate |
|
Severe (> 14 or symptomatic)
|
IV fluids + Bisphosphonate + Calcitonin; TRANSFER
|
Step-by-Step Treatment Protocol
| Step | Treatment | Purpose | Onset |
|---|---|---|---|
| 1 |
IV Normal Saline
|
Volume expansion; promote calciuresis |
Immediate
|
| 2 |
Furosemide
|
Enhance calcium excretion (only after rehydration) |
Hours
|
| 3 |
Calcitonin
|
Rapid Ca lowering |
4-6 hrs
|
| 4 |
Bisphosphonate
|
Sustained Ca lowering |
24-72 hrs
|
| 5 |
Steroids (if indicated)
|
Specific causes |
Days
|
| 6 |
Dialysis (if severe/refractory)
|
Direct Ca removal |
Immediate
|
Step 1: IV Fluid Resuscitation
| Parameter | Details |
|---|---|
|
Fluid
|
Normal Saline 0.9% |
|
Rate
|
200-500 mL/hr initially |
|
Volume
|
3-6 L in first 24 hrs |
|
Goal
|
Urine output 100-150 mL/hr |
|
Caution
|
Heart failure, CKD β monitor for overload |
π Patients are often severely dehydrated β aggressive hydration is first priority
Step 2: Furosemide (After Rehydration)
| Parameter | Details |
|---|---|
|
Dose
|
20-40 mg IV |
|
Timing
|
Only AFTER adequate volume resuscitation |
|
Purpose
|
Enhance calciuresis |
|
Frequency
|
Every 6-12 hrs as needed |
|
Monitor
|
Electrolytes (KβΊ, Mg²βΊ), volume status |
β οΈ Do NOT give Furosemide before hydration β worsens dehydration
Step 3: Calcitonin (Rapid Onset)
| Parameter | Details |
|---|---|
|
Dose
|
4-8 IU/kg |
|
Route
|
SC or IM |
|
Frequency
|
Every 6-12 hours |
|
Onset
|
4-6 hours |
|
Ca reduction
|
1-2 mg/dL |
|
Duration
|
Tachyphylaxis in 48-72 hrs (effect wears off) |
π Calcitonin works fast but effect is short-lived; use as bridge to bisphosphonate
Step 4: Bisphosphonate (Sustained Effect)
| Drug | Dose | Route | Onset | Duration |
|---|---|---|---|---|
|
Zoledronic Acid
|
4 mg
|
IV over 15 min
|
24-72 hrs
|
2-4 weeks
|
|
Pamidronate
|
60-90 mg
|
IV over 2-4 hrs
|
24-72 hrs
|
2-4 weeks
|
| Renal Adjustment | Zoledronic Acid |
|---|---|
| CrCl 60-89 | 4 mg |
| CrCl 50-59 | 3.5 mg |
| CrCl 40-49 | 3.3 mg |
| CrCl 30-39 | 3.0 mg |
| CrCl < 30 | Not recommended |
π Zoledronic Acid is preferred if available (single dose, faster infusion)
Step 5: Steroids (Specific Indications)
| Indication | Drug | Dose |
|---|---|---|
|
Granulomatous disease (Sarcoidosis, TB)
|
Hydrocortisone or Prednisolone |
40-60 mg/day
|
|
Vitamin D toxicity
|
||
|
Hematologic malignancy (Myeloma, Lymphoma)
|
π Steroids reduce intestinal calcium absorption and calcitriol production
Step 6: Dialysis (Severe/Refractory)
| Indication |
|---|
| Ca > 18 mg/dL |
| Refractory to medical therapy |
| Heart failure preventing fluid resuscitation |
| Severe renal impairment |
| Life-threatening symptoms |
| Modality | Details |
|---|---|
|
Hemodialysis
|
Low-calcium or calcium-free dialysate |
Other Treatments
| Treatment | Indication |
|---|---|
|
Denosumab
|
Malignancy-related; if bisphosphonates contraindicated |
|
Cinacalcet
|
Primary hyperparathyroidism (if surgery not possible) |
|
Phosphate
|
Generally avoided (risk of calcification); only if phosphate low |
Monitoring
| Parameter | Frequency |
|---|---|
| Calcium |
Every 4-6 hrs initially
|
| Creatinine |
Daily
|
| Electrolytes (KβΊ, Mg²βΊ, POβ) |
Daily
|
| Volume status |
Continuous
|
| Urine output |
Hourly
|
Primary Care Summary β Hypercalcemia
| Scenario | Action |
|---|---|
|
Mild (10.5-12), asymptomatic
|
Encourage oral hydration; investigate cause; monitor |
|
Moderate (12-14)
|
IV NS 150-200 mL/hr; TRANSFER
|
|
Severe (> 14) or symptomatic
|
IV NS aggressively; Calcitonin if available; TRANSFER urgently
|
Transfer Indications
| Indication |
|---|
| Ca > 14 mg/dL |
| Symptomatic (confusion, arrhythmias) |
| Renal impairment |
| Need for bisphosphonate/dialysis |
| Unknown cause requiring workup |
π QUICK REFERENCE CARDS
π΄ HYPERKALEMIA QUICK REFERENCE
text
βββββββββββββββββββββββββββββββββββββββββββββββββββββββββββββββββββββββββ
β HYPERKALEMIA EMERGENCY β
β ββββββββββββββββββββββββββββββββββββββββββββββββββββββββββββββββββββββββ£
β β
β IF KβΊ ≥ 6.5 OR ECG CHANGES OR >7 with or without ECG changes: β
β β
β βββββββββββββββββββββββββββββββββββββββββββββββββββββββββββββββββββ β
β β STEP 1: STABILIZE HEART β β
β β → Calcium Gluconate 10% β 10 mL IV over 2-3 min β β
β β → Repeat in 5-10 min if ECG changes persist β β
β βββββββββββββββββββββββββββββββββββββββββββββββββββββββββββββββββββ β
β β
β βββββββββββββββββββββββββββββββββββββββββββββββββββββββββββββββββββ β
β β STEP 2: SHIFT KβΊ INTO CELLS β β
β β → Regular Insulin 10 U IV + 50% Dextrose 50 mL IV β β
β β → Salbutamol 10-20 mg nebulized β β
β β → NaHCOβ 50-100 mEq IV (only if acidotic) β β
β βββββββββββββββββββββββββββββββββββββββββββββββββββββββββββββββββββ β
β β
β βββββββββββββββββββββββββββββββββββββββββββββββββββββββββββββββββββ β
β β STEP 3: REMOVE KβΊ FROM BODY β β
β β → Furosemide 40-80 mg IV (if urine output present) β β
β β → Kayexalate 30 g PO/PR (slow; not for acute) β β
β β → DIALYSIS (definitive β if KβΊ > 6.5 or not responding) β β
β βββββββββββββββββββββββββββββββββββββββββββββββββββββββββββββββββββ β
β β
β π TRANSFER for dialysis if KβΊ > 6.5 or refractory β
β β
βββββββββββββββββββββββββββββββββββββββββββββββββββββββββββββββββββββββββ
π΅ HYPONATREMIA QUICK REFERENCE
| Severity | Action |
|---|---|
|
Seizures/Coma
|
3% NaCl 100 mL bolus over 10 min (repeat ×2 if needed) |
|
Symptomatic
|
3% NaCl infusion; target rise 1-2 mEq/L/hr |
|
Hypovolemic
|
Normal Saline |
|
Euvolemic (SIADH)
|
Fluid restriction |
|
Hypervolemic (HF, Cirrhosis)
|
Fluid restriction + Diuretics |
|
Chronic (> 48 hrs)
|
Max correction 8 mEq/L in 24 hrs
|
π’ HYPOCALCEMIA QUICK REFERENCE
| Severity | Action |
|---|---|
|
Tetany / Seizures / Laryngospasm
|
Calcium Gluconate 10% β 10-20 mL IV over 10-20 min |
|
Mild/Asymptomatic
|
Oral Calcium 1-2 g/day + Vitamin D |
|
Always check
|
Magnesium (correct if low) |
|
Post-thyroidectomy
|
Monitor Ca q6-12h; IV calcium PRN |
π‘ HYPERCALCEMIA QUICK REFERENCE
| Severity | Action |
|---|---|
|
Mild (< 12)
|
Hydration; treat cause |
|
Moderate (12-14)
|
NS 200-500 mL/hr; consider bisphosphonate |
|
Severe (> 14)
|
NS aggressively + Calcitonin + Bisphosphonate + TRANSFER
|
|
Refractory
|
Dialysis |
π DRUG DOSING QUICK REFERENCE
| Drug | Dose | Indication |
|---|---|---|
|
Calcium Gluconate 10%
|
10-20 mL IV
|
Hyperkalemia, Hypocalcemia |
|
Insulin + Dextrose
|
10 U + 50 mL 50% Dextrose
|
Hyperkalemia |
|
Salbutamol nebulized
|
10-20 mg
|
Hyperkalemia |
|
Furosemide
|
40-80 mg IV
|
Hyperkalemia, Hypercalcemia |
|
3% NaCl
|
100-150 mL bolus
|
Severe hyponatremia |
|
Zoledronic Acid
|
4 mg IV
|
Hypercalcemia |
|
Calcitonin
|
4-8 IU/kg SC/IM
|
Hypercalcemia |
|
Magnesium Sulfate 50%
|
2-4 g IV
|
Hypomagnesemia |
β οΈ CRITICAL WARNINGS
| β NEVER | β ALWAYS |
|---|---|
| Delay Calcium Gluconate if KβΊ ≥ 6.5 + ECG changes | Get ECG in hyperkalemia |
| Give Insulin without Dextrose (unless hyperglycemic) | Monitor glucose after Insulin-Dextrose |
| Correct chronic hyponatremia > 8 mEq/L in 24 hrs | Correct slowly to prevent ODS |
| Give Furosemide before hydration in hypercalcemia | Rehydrate first, then diuretics |
| Forget to check Magnesium in refractory hypokalemia/hypocalcemia | Correct Mg²βΊ concurrently |
| Give rapid IV Calcium in digoxin toxicity | Slow infusion if on Digoxin |
π’ KEY FORMULAS
| Calculation | Formula |
|---|---|
|
Corrected NaβΊ (for hyperglycemia)
|
Measured NaβΊ + [1.6 × (Glucose - 100) / 100] |
|
Corrected Ca²βΊ (for albumin)
|
Measured Ca + 0.8 × (4 - Albumin) |
|
Water Deficit (Hypernatremia)
|
TBW × [(Measured NaβΊ / 140) - 1] |
|
TBW
|
Weight × 0.6 (men) or 0.5 (women/elderly) |
|
KβΊ Deficit (rough estimate)
|
For each 0.3 mEq/L drop below 3.5 → ~100 mEq deficit |
π ABBREVIATIONS
| Abbreviation | Full Form |
|---|---|
|
NaβΊ
|
Sodium |
|
KβΊ
|
Potassium |
|
Ca²βΊ
|
Calcium |
|
Mg²βΊ
|
Magnesium |
|
POβ³β»
|
Phosphate |
|
HCOββ»
|
Bicarbonate |
|
TBW
|
Total Body Water |
|
ECG
|
Electrocardiogram |
|
QT
|
QT interval on ECG |
|
SIADH
|
Syndrome of Inappropriate ADH Secretion |
|
ADH
|
Antidiuretic Hormone |
|
PTH
|
Parathyroid Hormone |
|
PTHrP
|
PTH-related Peptide |
|
RTA
|
Renal Tubular Acidosis |
|
CKD
|
Chronic Kidney Disease |
|
AKI
|
Acute Kidney Injury |
|
DKA
|
Diabetic Ketoacidosis |
|
HHS
|
Hyperosmolar Hyperglycemic State |
|
DI
|
Diabetes Insipidus |
|
ODS
|
Osmotic Demyelination Syndrome |
|
GBS
|
Guillain-Barré Syndrome |
|
PAC
|
Premature Atrial Contraction |
|
PVC
|
Premature Ventricular Contraction |
|
AF
|
Atrial Fibrillation |
|
VT
|
Ventricular Tachycardia |
|
VF
|
Ventricular Fibrillation |
|
NS
|
Normal Saline |
|
D5W
|
5% Dextrose in Water |
|
CRRT
|
Continuous Renal Replacement Therapy |
|
ACE-I
|
Angiotensin-Converting Enzyme Inhibitor |
|
ARB
|
Angiotensin Receptor Blocker |
|
TMP-SMX
|
Trimethoprim-Sulfamethoxazole |
|
SSRI
|
Selective Serotonin Reuptake Inhibitor |
|
DDAVP
|
Desmopressin |
|
SC
|
Subcutaneous |
|
IM
|
Intramuscular |
|
IV
|
Intravenous |
|
PO
|
Per Oral |
|
PR
|
Per Rectum |
|
UOP
|
Urine Output |
|
JVP
|
Jugular Venous Pressure |
|
TB
|
Tuberculosis |
|
SAH
|
Subarachnoid Hemorrhage |
π REFERENCES
| Guideline/Source | Year |
|---|---|
| AHA/ACC Guidelines on Hyperkalemia Management | 2023 |
| European Guidelines on Hyponatremia |
2014 (Updated 2023)
|
| Kidney Disease Improving Global Outcomes (KDIGO) |
Current
|
| UpToDate Clinical Decision Support |
Current
|
| API Textbook of Medicine |
Latest Edition
|
| Harrison's Principles of Internal Medicine |
Latest Edition
|
| Oxford Handbook of Clinical Medicine |
Latest Edition
|
Document Version: 1.0
India-Specific Notes:
- CKD is very prevalent β hyperkalemia is common
- ACE-I/ARB use widespread β monitor KβΊ
- Vitamin D deficiency very common β consider in hypocalcemia
- TB can cause hypercalcemia (granulomatous) and hyponatremia (SIADH)
- Traditional medicines may contain electrolyte-altering substances
Disclaimer: This protocol provides general guidance. Clinical judgment must be exercised. Local protocols and resources may vary.
π‘οΈ
Medical Advisory
Clinical guidelines are subject to change. Physicians should exercise their regular clinical judgment. This protocol does not replace individual institutional policies. Verified for Q1 2026.
Content Feedback
Is this information helpful?
Help us improve our clinical database for the medical community.